Recent Advances across the Cancer Immunotherapy Landscape

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across cancer immunotherapy. Different innovations and collaborations among the main participants in the field are illustrated. The corresponding clinical trials scenario is depicted, along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing t

Table of Contents

Recent Advances across the Cancer Immunotherapy LandscapeKey Developments in Cancer ImmunotherapiesCX-2029 Reaches Developmental Milestone in Oncology CollaborationUnique Protease Triggered Immune Activator (ProTIA) Platform for Cancer TherapyGilead Sciences to Buy Kite Pharma for $11.9 BillionEnhancing the Memory of Immune Cells for Cancer TherapyClinical Trial Analysis and Industry InteractionsAnalysis of Key Cancer Immunotherapy Clinical StudiesSummary of Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.